PSMA-T4

PSMA-T4 is a novel prostate-specific membrane antigen (PSMA)-targeting radiopharmaceutical developed by the Radioisotope Centre POLATOM (National Centre for Nuclear Research) for the diagnostic imaging of prostate cancer. The compound consists of a Glu-CO-Lys binding motif conjugated to a HYNIC (6-hydrazinonicotinic acid) chelator via a specific linker sequence that includes L-tryptophan (L-Trp). This L-Trp linker is designed to enhance the lipophilicity and binding affinity of the molecule while significantly reducing undesirable accumulation in the kidneys. Formulated as a pharmaceutical kit for labeling with Technetium-99m, [99mTc]Tc-PSMA-T4 enables high-resolution single-photon emission computed tomography (SPECT) imaging to detect metastatic lesions in patients with prostate cancer. It is currently being evaluated in late-stage clinical trials to provide a cost-effective and widely accessible alternative to PET-based PSMA imaging.

Brand names

PSMA-T4 kitPSMA-T-4 kitPSMA-T 4 kit

Other names

PSMA-HYNICGlu-CO-Lys-L-Trp-4-Amc-HYNICGlu-CO-Lys-L-Trp4-Amc-HYNICGlu-CO-Lys-L-Trp 4-Amc-HYNIC99mTc-PSMA-T4